Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

109.24 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 109.24
Bid (Size) 102.88 (1)
Ask (Size) 113.33 (1)
Prev. Close 109.24
Today's Range 109.24 - 109.24
52wk Range 71.88 - 112.12
Shares Outstanding 94,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
4 Analysts Have This to Say About Neurocrine Biosciences
Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings: 
Via Benzinga

Performance

YTD
+23.48%
+23.48%
1 Month
+6.04%
+6.04%
3 Month
+11.13%
+11.13%
6 Month
+12.56%
+12.56%
1 Year
+8.28%
+8.28%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022
Via Benzinga
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
Via Investor's Business Daily
Neurocrine Biosciences Buys UK-Based Hormone Therapy Player
Via Benzinga
Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance
Via Benzinga
S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms
Via Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
Neurocrine Leads 5 Stocks To Watch In Sickly Market
Via Investor's Business Daily
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Via Benzinga
Neurocrine Biosciences Shelves Key Drug; Will It Overshadow The Earnings Beat?
Via Investor's Business Daily
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
Via Investor's Business Daily
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
Dow Jones Giant Amgen Leads 5 Stocks To Watch Near Buy Points
Via Investor's Business Daily
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
Via Benzinga
Neurocrine Biosciences Earnings Perspective: Return On Capital Employed
Via Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
Via Benzinga
Neurocrine Biosciences: Q1 Earnings Insights
Via Benzinga
Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET
Via Benzinga
What 8 Analyst Ratings Have To Say About Neurocrine Biosciences
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
Via Benzinga
Where Neurocrine Biosciences Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022
Via Benzinga
Looking Into Neurocrine Biosciences's Return On Capital Employed
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.